uniQure GAAP EPS of -$1.38 misses by $0.50, revenue of $3.7M misses by $1.44M
Source: SeekingAlpha
2025-11-10 07:07:43 ET
More on uniQure
- UniQure: Controversy Abounds As Stock Price Halves On FDA News
- uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)
- uniQure: Further Upside Likely As The Opportunity Becomes Better Understood
- uniQure Q3 2025 Earnings Preview
- uniQure stock falls after FDA feedback on gene therapy application
Read the full article on Seeking Alpha
For further details see:
uniQure GAAP EPS of -$1.38 misses by $0.50, revenue of $3.7M misses by $1.44M
uniQure N.V.
NASDAQ: QURE
QURE Trading
-1.52% G/L:
$19.73 Last:
171,106 Volume:
$19.85 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
